Detalhe da pesquisa
1.
p53 opens the mitochondrial permeability transition pore to trigger necrosis.
Cell
; 149(7): 1536-48, 2012 Jun 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-22726440
2.
Targeting RAS in pediatric cancer: is it becoming a reality?
Curr Opin Pediatr
; 32(1): 48-56, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31815779
3.
An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance.
Genes Dev
; 25(15): 1628-40, 2011 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21828272
4.
Sensitization to Ionizing Radiation by MEK Inhibition Is Dependent on SNAI2 in Fusion-Negative Rhabdomyosarcoma.
Mol Cancer Ther
; 22(1): 123-134, 2023 01 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36162055
5.
Redundant Signaling as the Predominant Mechanism for Resistance to Antibodies Targeting the Type-I Insulin-Like Growth Factor Receptor in Cells Derived from Childhood Sarcoma.
Mol Cancer Ther
; 22(4): 539-550, 2023 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36696581
6.
The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models.
Clin Cancer Res
; 29(2): 472-487, 2023 01 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36322002
7.
Approaches to identifying drug resistance mechanisms to clinically relevant treatments in childhood rhabdomyosarcoma.
Cancer Drug Resist
; 5: 80-89, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35450020
8.
Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.
Oncogene
; 41(21): 2973-2983, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35459782
9.
Vertical Inhibition of the RAF-MEK-ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma.
Mol Cancer Ther
; 21(1): 170-183, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34737198
10.
SNAI2-Mediated Repression of BIM Protects Rhabdomyosarcoma from Ionizing Radiation.
Cancer Res
; 81(21): 5451-5463, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34462275
11.
The mitochondrial p53 pathway.
Biochim Biophys Acta
; 1787(5): 414-20, 2009 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-19007744
12.
Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer.
Sci Signal
; 12(590)2019 07 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-31311847
13.
KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism.
Cancer Cell
; 34(5): 807-822.e7, 2018 11 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30423298
14.
Repression of cyclin D1 as a target for germ cell tumors.
Int J Oncol
; 30(2): 333-40, 2007 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17203214
15.
Correction: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.
Oncogene
; 41(21): 3037, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35534540
16.
Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies.
Sci Signal
; 10(498)2017 Sep 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-28951536
17.
Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms.
Cancer Res
; 75(10): 2109-19, 2015 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25808866
18.
Identification of p53 in mitochondria.
Methods Mol Biol
; 962: 75-84, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23150438
19.
Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274.
Cancer Lett
; 289(2): 228-36, 2010 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-19783361
20.
Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.
Clin Cancer Res
; 16(3): 912-23, 2010 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20103665